Literature DB >> 1782978

Flecainide: evidence of non-linear kinetics.

G Boriani1, E Strocchi, A Capucci, R Callivà, L Frabetti, E Ambrosioni, B Magnani.   

Abstract

The pharmacokinetics of flecainide has been studied in 12 patients with ventricular arrhythmias, both after single administration and during chronic treatment. Both the half-life and the AUC were significantly increased during chronic treatment. This suggests that the kinetics of flecainide might be non-linear also in patients with normal kidney and liver function. The increase in plasma flecainide levels during chronic treatment could not be predicted, so close monitoring of its plasma levels is advisable.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1782978     DOI: 10.1007/BF00280107

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

Review 1.  Drug therapy. Flecainide.

Authors:  D M Roden; R L Woosley
Journal:  N Engl J Med       Date:  1986-07-03       Impact factor: 91.245

2.  Determination of debrisoquine and its 4-hydroxy metabolite in urine by high-performance liquid chromatography.

Authors:  P M Harrison; A M Tonkin; S T Dixon; A J McLean
Journal:  J Chromatogr       Date:  1986-01-10

3.  Pharmacokinetics of flecainide in patients with cirrhosis of the liver.

Authors:  R L McQuinn; P J Pentikäinen; S F Chang; G J Conard
Journal:  Clin Pharmacol Ther       Date:  1988-11       Impact factor: 6.875

4.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

5.  Pharmacokinetics of flecainide in patients with mild and moderate renal failure compared with patients with normal renal function.

Authors:  J Braun; J R Kollert; J U Becker
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 6.  Metabolism of flecainide.

Authors:  G J Conard; R E Ober
Journal:  Am J Cardiol       Date:  1984-02-27       Impact factor: 2.778

7.  Flecainide pharmacokinetics after multiple dosing in patients with impaired renal function.

Authors:  S C Forland; R E Cutler; R L McQuinn; D C Kvam; A M Miller; G J Conard; S Parish
Journal:  J Clin Pharmacol       Date:  1988-08       Impact factor: 3.126

8.  Development of fluoroimmunoassays for flecainide.

Authors:  R E Coxon; A J Hodgkinson; A M Sidki; J Landon; G Gallacher
Journal:  Ther Drug Monit       Date:  1987-12       Impact factor: 3.681

9.  Oral flecainide pharmacokinetics in patients with impaired renal function.

Authors:  S C Forland; E Burgess; A D Blair; R E Cutler; D C Kvam; C E Weeks; J M Fox; G J Conard
Journal:  J Clin Pharmacol       Date:  1988-03       Impact factor: 3.126

10.  Pharmacokinetics of flecainide acetate in patients with severe renal impairment.

Authors:  A J Williams; R L McQuinn; J Walls
Journal:  Clin Pharmacol Ther       Date:  1988-04       Impact factor: 6.875

View more
  3 in total

1.  Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects.

Authors:  Kyoung Soo Lim; Joo-Youn Cho; In-Jin Jang; Bo-Hyung Kim; JaeWoo Kim; Ji-Young Jeon; Yu-Mi Tae; SoJeong Yi; SoYoung Eum; Sang-Goo Shin; Kyung-Sang Yu
Journal:  Br J Clin Pharmacol       Date:  2008-07-24       Impact factor: 4.335

Review 2.  Safety of flecainide.

Authors:  Juan Tamargo; Alessandro Capucci; Philippe Mabo
Journal:  Drug Saf       Date:  2012-04-01       Impact factor: 5.606

3.  Flecainide-induced Increase in QRS Duration and Proarrhythmia during Exercise.

Authors:  P Bordier; S Garrigue; V Bernard; M Haissaguerre; H Douard; J P Broustet; J Clementy
Journal:  Clin Drug Investig       Date:  1997-06       Impact factor: 2.859

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.